ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PROK ProKidney Corp.

Trading 08-19 12:44:46 EDT

1.44

+0.06

+3.99%

High1.45	Low1.38	Vol552.53K
Open1.42	D1 Closing1.38	Amplitude4.71%
Mkt Cap433.83M	Tradable Cap133.85M	Total Shares302.32M
T/O785.08K	T/O Rate0.59%	Tradable Shares93.27M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PROK","market":"US","secType":"STK","nameCN":"ProKidney Corp.","latestPrice":1.435,"timestamp":1787157881958,"preClose":1.38,"halted":0,"volume":552534,"delay":0,"changeRate":0.03985507246376824,"floatShares":93273799,"shares":302322700,"eps":-0.556619,"marketStatus":"Trading","change":0.055,"latestTime":"08-19 12:44:46 EDT","open":1.42,"high":1.445,"low":1.38,"amount":785081.9130102,"amplitude":0.047101,"askPrice":1.44,"askSize":2885,"bidPrice":1.43,"bidSize":1806,"shortable":3,"etf":0,"ttmEps":-0.556619,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787169600000},"marketStatusCode":2,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":1.38,"preHourTrading":{"tag":"盘前","latestPrice":1.43,"preClose":1.38,"latestTime":"09:28 EDT","volume":1192,"amount":1700.4199456,"timestamp":1787146080036,"change":0.05,"changeRate":0.036232,"amplitude":0.021739},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.38,"latestTime":"19:34 EDT","volume":14134,"amount":19845.4244,"timestamp":1787096049705,"change":0.02,"changeRate":0.014493,"amplitude":0.021739},"volumeRatio":0.877518,"impliedVol":0.6736,"impliedVolPercentile":0.2032},"requestUrl":"/m/hq/s/PROK/wiki","defaultTab":"wiki","newsList":[{"id":"2659162006","title":"Eledon Pharmaceuticals Q2 Net Loss Widens on Warrant Liability Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162006?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652214,"startTime":"0","endTime":"0","summary":"Eledon Pharmaceuticals Q2 net loss widens on warrant liability changesOverviewUS biotech reported Q2 net loss widened yr/yr, driven by non-cash warrant liability changesOperating expenses for Q2 fell ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A158:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","UNCY","ELDN","BK4539","ACHV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150152","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), Eton Pharmaceuticals (ETON) and Dyadic International (DYAI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150152?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:40","pubTimestamp":1786628423,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK), Eton Pharmaceuticals (ETON) and ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prokidney-prok-eton-pharmaceuticals-eton-and-dyadic-international-dyai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prokidney-prok-eton-pharmaceuticals-eton-and-dyadic-international-dyai-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","DYAI","PROK","BK4139","XBI","BK4581","XLV","HCSG","LU0128526141.USD","LU0029874061.USD","BK4585","BK4007","BK4137","LABU","ETON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659215183","title":"MiNK Therapeutics Q2 Loss Narrows on Expense Discipline","url":"https://stock-news.laohu8.com/highlight/detail?id=2659215183","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659215183?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:40","pubTimestamp":1786621208,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Q2 loss narrows on expense disciplineOverviewUS biopharma firm's Q2 net loss narrowed yr/yr, reflecting continued expense disciplineCompany advanced lead cell therapy agenT-797 into ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4539","PROK","BK4139","IPSC","BK4505","SANA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659194900","title":"MaxCyte Q2 Revenue Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659194900","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659194900?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:20","pubTimestamp":1786566040,"startTime":"0","endTime":"0","summary":"MaxCyte Q2 revenue beats estimatesOverviewUS cell engineering platform's Q2 revenue fell 15% yr/yr but beat analyst expectationsQ2 adjusted EBITDA loss was larger than analyst consensusCompany repurch","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44911J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEMS","PROK","BK4139","BK4588","CANC","LEGN","MXCT","BK4121","BK4585","QTRX","BK4539","MEDI","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900653","title":"Atara Biotherapeutics Q2 Revenue Falls on Deferred Revenue Recognition","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900653","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900653?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:14","pubTimestamp":1786565663,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Q2 revenue falls on deferred revenue recognitionOverviewUS T-cell immunotherapy developer's Q2 revenue beat analyst expectations, but fell sharply yr/yrCompany reported Q2 net lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N449110:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","AARD","BK4007","BK4139","PLRX","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658143972","title":"Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658143972","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658143972?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:09","pubTimestamp":1786536564,"startTime":"0","endTime":"0","summary":"Century Therapeutics Q2 net loss misses estimates on lease termination lossOverviewU.S. cell therapy developer's Q2 net loss widened yr/yr, missing analyst expectationsQ2 operating income missed analy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4539","IPSC","NKTX","BK4139","SANA","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974615","title":"Unicycive Therapeutics Q2 Net Loss Narrows on Warrant Liability Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974615","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974615?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:31","pubTimestamp":1786534264,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q2 net loss narrows on warrant liability changeOverviewUS kidney disease biotech's Q2 net loss narrowed from prior yearNet loss decline attributed to change in fair value of war","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490ED:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCYX","BK4139","ACHV","BK4007","UNCY","PROK","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971411","title":"Humacyte Q2 Net Loss Widens on Inventory, Production Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971411","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971411?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:11","pubTimestamp":1786533109,"startTime":"0","endTime":"0","summary":"Humacyte Q2 net loss widens on inventory, production costsOverviewU.S. bioengineered tissue maker's Q2 net loss widened, missing analyst expectationsQ2 product revenue for Symvess rose to $0.4 mln fro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N4490DQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4139","PLRX","PROK","HUMA","BK4563","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658699254","title":"Legend Biotech Q2 Revenue Beats Estimates on Commercial Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2658699254","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658699254?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:09","pubTimestamp":1786446570,"startTime":"0","endTime":"0","summary":"Legend Biotech Q2 revenue beats estimates on commercial expansionOverviewCell therapy company's Q2 revenue rose sharply, beating analyst expectationsAdjusted EPS for Q2 beat analyst expectations, refl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711040.USD","LEGN","LU1571399168.USD","BK4007","LU1670710661.SGD","FTXH","LU1670710588.SGD","LU1989771016.USD","BK4139","IE00BFTCPJ56.SGD","LU0321505439.SGD","MEDI","BK4534","LU0225284248.USD","LU1718418525.SGD","LU0114720955.EUR","LU1074936037.SGD","LU0237698245.USD","LU1032466523.USD","BK4588","LU0456855351.SGD","LU1868836757.USD","LU2242652126.USD","LU0868494617.USD","LU0321505868.SGD","MEMS","LU0985481810.HKD","LU1323610961.USD","LU1868836914.USD","IHE","BMY","PROK","LU1261432733.SGD","BK4585","LU1291159041.SGD","LU1983299246.USD","LU2242646821.SGD","LU0096364046.USD","LU0267386448.USD","BBIO","BK4559","CANC","LU1670711123.USD","LU1868837300.USD","IE0009355771.USD","IE0002141913.USD","LU1585245621.USD","LU2596442595.SGD","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658954473","title":"Vera Therapeutics Q2 Loss Widens Less than Expected","url":"https://stock-news.laohu8.com/highlight/detail?id=2658954473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658954473?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:07","pubTimestamp":1786396033,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Q2 loss widens less than expectedOverviewUS biotech's Q2 EPS widened less than analyst expectationsCompany launched TRUTAKNA, first FDA-approved BAFF and APRIL inhibitor for IgA neph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470ZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139","BK4588","SANA","VERA","LU2324357040.USD","BK4585","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951674","title":"Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951674","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951674?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:32","pubTimestamp":1786393955,"startTime":"0","endTime":"0","summary":"Biotech firm Nkarta posts Q2 net loss; cash runway into 2029OverviewUS biotech firm reported Q2 net loss of $40.4 mln, or $0.54 per shareCompany ended Q2 with $243.2 mln in cash and investments, expec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","OLMA","BK4139","BK4505","NKTX","MGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951871","title":"ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951871","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951871?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:25","pubTimestamp":1786393514,"startTime":"0","endTime":"0","summary":"ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 15.38 percent decrease over losses of $(0.13) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61093224/prokidney-q2-eps-0-15-misses-0-14-estimate-sales-150-000k-beat-149-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ProKidney Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $150.000K Beat $149.000K Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658518889","title":"Cell Therapy Developer ProKidney's Q2 Operating Loss Widens as Trial Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658518889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658518889?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:22","pubTimestamp":1786393334,"startTime":"0","endTime":"0","summary":"Cell therapy developer ProKidney's Q2 operating loss widens as trial costs riseOverviewU.S. cell therapy developer's Q2 operating expenses rose, driven by clinical study and manufacturing costsNet los","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N4470W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","BK4139","CANC","PROK","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658886959","title":"ProKidney Q2 Operating Income USD -48.373 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658886959","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658886959?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:06","pubTimestamp":1786392363,"startTime":"0","endTime":"0","summary":"BRIEF-ProKidney Q2 Operating Income USD -48.373 MillionAug 10 (Reuters) - ProKidney Q2 operating expenses USD 48.523 million.Q2 pretax profit USD -46.436 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXFQN05L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658956052","title":"ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658956052","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658956052?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:05","pubTimestamp":1786392303,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA8TFD8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649621057","title":"July 2026 Penny Stocks With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2649621057","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649621057?lang=en_us&edition=fundamental","pubTime":"2026-07-06 19:05","pubTimestamp":1783335935,"startTime":"0","endTime":"0","summary":"The market has climbed 1.6% in the last 7 days and is up 19% over the last 12 months, with earnings forecast to grow by 18% annually. For investors willing to explore beyond the big names, penny stocks — often smaller or newer companies — can be full of surprises. While the term might evoke earlier market trends, these stocks can provide a mix of affordability and growth potential when paired with strong financials.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/july-2026-penny-stocks-with-promising-potential","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/july-2026-penny-stocks-with-promising-potential","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","SIGA","BK4102","BK4583","HFFG","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641447144","title":"Identiv And Two Other Penny Stocks To Watch Closely","url":"https://stock-news.laohu8.com/highlight/detail?id=2641447144","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641447144?lang=en_us&edition=fundamental","pubTime":"2026-06-06 01:15","pubTimestamp":1780679717,"startTime":"0","endTime":"0","summary":"The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 16% annually. For investors willing to look beyond the big names, penny stocks can present intriguing opportunities for growth at lower price points. While often associated with smaller or newer companies, these stocks can offer potential upside when backed by strong fundamentals and sound balance sheets.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/identiv-and-two-other-penny-stocks-to-watch-closely","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/identiv-and-two-other-penny-stocks-to-watch-closely","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4204","INVE","PROK","BK4190","BK4157","HERE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640948847","title":"ProKidney names Kenneth Locke chief technical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640948847","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640948847?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:06","pubTimestamp":1780402007,"startTime":"0","endTime":"0","summary":"ProKidney named Kenneth Locke as chief technical officer as it prepares for a pivotal topline readout for rilparencel in Q2 2027.Locke joins from Carisma Therapeutics, where he led CMC, quality, regulatory functions, and technical strategy for first-in-human CAR myeloid programs.He previously held cell-therapy manufacturing and supply-chain leadership roles at Celgene, now Bristol Myers Squibb, and at Novartis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2kfWDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","LU1571399168.USD","LU0237698245.USD","LU1430594728.SGD","LU1093756325.SGD","LU2133065610.SGD","LU1670710588.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","CARM","LU1093756168.USD","LU2242652126.USD","LU0061475181.USD","LU0306806265.USD","LU0096364046.USD","LU0321505439.SGD","LU0225771236.USD","LU0321505868.SGD","LU0456855351.SGD","LU1883839398.USD","BMY","LU0868494617.USD","LU1670711040.USD","LU1868836757.USD","BK4007","BK4532","LU1291159041.SGD","LU1585245621.USD","BK4534","LU0225284248.USD","LU0267386448.USD","LU2242646821.SGD","LU1983299246.USD","LU0985481810.HKD","LU1323610961.USD","LU1074936037.SGD","LU1868837300.USD","LU1670711123.USD","LU1868836914.USD","IE00BFTCPJ56.SGD","LU0306807586.USD","LU0432979614.USD","BK4585","LU1670710661.SGD","IE00BFXG1179.USD","LU2360032135.SGD","BK4139","IE0002141913.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640104079","title":"ProKidney Appoints Kenneth Locke as Chief Technical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640104079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640104079?lang=en_us&edition=fundamental","pubTime":"2026-06-02 20:00","pubTimestamp":1780401605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA5GV5FD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PROK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639672427","title":"ProKidney shareholders elect directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639672427","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639672427?lang=en_us&edition=fundamental","pubTime":"2026-05-30 04:03","pubTimestamp":1780085008,"startTime":"0","endTime":"0","summary":"ProKidney held its annual shareholder meeting on May 28, 2026.Shareholders backed the selection of three director nominees to serve three-year terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLbJqLBg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.prokidney.com;investors.prokidney.com","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":-0.1481},{"period":"3month","weight":-0.1834},{"period":"6month","weight":-0.3699},{"period":"1year","weight":-0.4567},{"period":"ytd","weight":-0.3839}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.022112},{"month":2,"riseRate":0.8,"avgChangeRate":0.049183},{"month":3,"riseRate":0.4,"avgChangeRate":-0.102405},{"month":4,"riseRate":0.6,"avgChangeRate":0.032646},{"month":5,"riseRate":0.6,"avgChangeRate":0.15052},{"month":6,"riseRate":0.4,"avgChangeRate":-0.086475},{"month":7,"riseRate":0.333333,"avgChangeRate":0.582213},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.098591},{"month":9,"riseRate":0.4,"avgChangeRate":-0.139421},{"month":10,"riseRate":0.6,"avgChangeRate":-0.082174},{"month":11,"riseRate":0.4,"avgChangeRate":-0.019735},{"month":12,"riseRate":0.6,"avgChangeRate":-0.066082}],"exchange":"NASDAQ","name":"ProKidney Corp.","nameEN":"ProKidney Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProKidney Corp.,PROK,ProKidney Corp.股票,ProKidney Corp.股票老虎,ProKidney Corp.股票老虎国际,ProKidney Corp.行情,ProKidney Corp.股票行情,ProKidney Corp.股价,ProKidney Corp.股市,ProKidney Corp.股票价格,ProKidney Corp.股票交易,ProKidney Corp.股票购买,ProKidney Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction